ClinicalTrials.gg
Active, not recruitingNCT06383585Updated Aug 14, 2026

3D DL Ozteo in the Detection of Osseous Changes in Patients With Inflammatory Arthritis

An interventional study of oZTEo in Inflammatory Arthritis, sponsored by Mayo Clinic. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-14.

Sponsored by Mayo Clinic · Not applicable, Interventional, and Diagnostic

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 413 studies in Arthritis with a site in United States — 38 open to participants now, 55 under way, 4 of them phase 3. Arthritis · United States.

Enrollment
270th of 337
25 · median 100
Started
2024
with 13 others
No phase
148 of 413
14 open now
Primary completion
2026-12
later than 18 of 51 live
Registered
388th of 413
by date

Among the 413 studies in Arthritis with a site in United States, this one is the 270th largest by enrollment of the 337 interventional ones that give a count, is one of 14 that started in 2024, is one of 148 with no phase, reaches primary completion later than 18 of the 51 other live ones, and was the 388th registered.

Arthritis

843 studies on the registry are indexed under Arthritis; 118 are open to participants now.

Browse Arthritis studies →

Open to participants now

38 of the 413 studies in Arthritis with a site in United States are open now. Recruiting first, the newest first:

33 more — sign in →

All 38 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 78 Arthritis studies recruiting now, 41 (53%) set no upper age limit and 20 (26%) stop at 75 or younger; 16 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 413 studies in Arthritis with a site in United States, or all of them as a file.
02

Study summary

This project intends to explore and validate the utility of new MRI pulse sequence, 3D DL oZTEo, in the detection of osseous erosions of the hand in patients with inflammatory arthritis. The detection of osseous structural changes, such as erosive disease, is routinely assessed in patients with rheumatic conditions such as rheumatoid arthritis, as it alters clinical management, and in some cases assists in diagnosis. Currently, this is most often assessed with radiography and conventional MRI.

Read the detailed description

This project intends to explore and validate the utility of new MRI pulse sequence, 3D DL oZTEo, in the detection of osseous erosions of the hand in patients with inflammatory arthritis.

03

Conditions studied

  • Inflammatory Arthritis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients ≥18 years of age
  • Hand radiographs performed within the past 3-6 months with imaging results available for analysis
  • Hand radiographs confirm the presence of bony erosions
  • Scheduled for a hand MRI as part of their routine clinical care at Mayo Clinic Rochester

Exclusion criteria

Exclusion Criteria:

- Less than18 years of age

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    oZTEo MRI pulse sequence

    All patients will have the FDA approved MRI pulse sequence, oZTEo, added to their already ordered standard of care MRI examination.

    Device: oZTEo

Interventions

  • DeviceoZTEo

    An FDA approved MRI pulse sequence, oZTEo, will be added to a standard of care MRI examination. The oZTEo pulse sequence will be anonymized and sent to GE Healthcare for the application of a deep learning algorithm, 3D DL.

    Also known as: 3D DL oZTEo

06

What researchers measure

Primary outcomes

  1. The binary (yes/no) presence of bony erosions as detected by hand MRI with and without the addition of the 3D DL oZTEo sequence.

    The primary outcome

    Time frame: 1 day

Secondary outcomes

  1. The number of erosions (continuous) as detected by hand MRI with and without the addition of the 3D DL oZTEo sequence.

    The secondary outcome

    Time frame: 1 day

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Dec 2026, 24 months after the start.

Of 134 non-industry interventional studies with no phase under Arthritis, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 57. This study's planned 24 months is below that.

Counting every sponsor, half of 167 studies reached it within 31 months; a quarter within 13 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2024
First posted
Apr 25, 2024
StartActual
Dec 5, 2024
Primary completionEst.
Dec 10, 2026
CompletionEst.
Dec 31, 2026
Last update
Aug 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06383585
Lead sponsor
Mayo Clinic
Collaborators
GE Healthcare
Responsible party
Naveen S. Murthy (Principal Investigator, Mayo Clinic) — Principal investigator
First posted
Apr 25, 2024
Start date
Dec 5, 2024
Primary completion
Dec 10, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Aug 14, 2026

Study contacts

Naveen Murthy, MD
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion